Sorin is now LivaNova. Learn more here

Mitroflow Valsalva Conduit

20_det_mcv_Cmax_v1.jpg

The innovative Mitroflow Valsalva Conduit is designed to provide a reproducible and easy solution for better outcomes by:

  1. Taking advantage of the Mitroflow proven hemodynamic and clinical results  
  2. Replicating the native sinus, reducing stress on the coronary anastomoses
  3. Encouraging natural formation of systolic vortex with sinus design

The Mitroflow Valsalva Conduit System consists of the:

  • Mitroflow Valsalva Conduit,
  • Mitroflow Aortic Pericardial Heart Valve

 

 

 

 

 

 

 

Features

The Mitroflow Valsalva Conduit provides: 

  • A graft specially designed to be coupled directly in the operating room with the Mitroflow valve, minimizing all the risks associated with the device manipulation during assembly and implantation, while avoiding increases in procedural time
  • A cuff to securely wrap around the Mitroflow valve sewing ring, avoiding the insertion of delicate sutures for the conduit-valve assembly
  • Commissure orientation alignment guide lines, ensuring consistent positioning of the Mitroflow valve within the conduit 
  • Replicated sinus of Valsalva1, reducing stress on the coronary anastomoses   
  • A sealed graft with no pre-clotting requirements
  • A graft impregnated with minimally cross-linked gelatin for faster healing, encouraging a secure neo-intimal attachment with reduced inflammatory response

The Mitroflow Aortic Pericardial Heart Valve has demonstrated:

  • Excellent valve hemodynamics2,3,4 
  • Proven durability5,6,7 

The Mitroflow Valsalva Conduit should be immersed in sterile saline for no longer than 5 minutes prior to implantation to improve its handling qualities.

References

  1. Hisada, et al. The Sinus of Valsalva Relieves Abnormal Stress on Aortic Valve Leaflets by Facilitating Smooth Closure. J Thorac Cardiovasc Surg. 2008;136:1528–35.e1.

  2. Asch FM, et al. Mitroflow Aortic Bioprosthesis 5-Year Follow-Up: North American Prospective Multicenter Study. Ann Thorac Surg. 2012;94:1198-1203.

  3. Jamieson WR, Forgie WR, Hayden RI et al. Hemodynamic performance of mitroflow aortic pericardial bioprosthesis – optimizing management for the small aortic annulus. J Thorac Cardiovasc Surg. 2010;58:69–75.

  4. Bleiziffer S, Eichinger WB, Hettich IM et al. Hemodynamic characterization of the Sorin Mitroflow pericardial bioprosthesis at rest and exercise. J Heart Valve Dis. 2009;18:95–100.

  5. The ISTHMUS Investigators. The Italian study on the Mitroflow postoperative results (ISTHMUS): A 20-year, multicentre evaluation of Mitroflow pericardial bioprosthesis. Eur J Cardiothorac Surg. 2011;39:18–26.

  6. Yankah C, Pasic M, Musci M et al. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg. 2008;136:688–96.

  7. Yankah, C. Mitroflow pericardial aortic bioprosthesis in patients younger than 60 years. J Thorac Cardiovasc Surg. 2010;140:e83–4.

Technical tips

  • The conduit is always 5 mm larger than the valve graft.1 

    • Example: 21mm Mitroflow valve fits a 26mm Valsalva Conduit
  • Use the standard Mitroflow Valve Sizers.
  • Size the annulus before suture placement.
  • Compatible valve sizes with the Mitroflow Valsalva Conduit: 21 mm - 27 mm.
  • Always wet the graft before cauterizing.
  • Refer to the Instructions for Use provided with the Mitroflow Valsalva Conduit for detailed information, warnings, precautions and possible adverse effects.

References

  1. Jamieson WR, Forgie WR, Hayden RI et al. Hemodynamic performance of mitroflow aortic pericardial bioprosthesis – optimizing management for the small aortic annulus. J Thorac Cardiovasc Surg. 2010;58:69–75.

Ordering information 

The Mitroflow Aortic Valve and Mitroflow Valsalva Conduit are sold separately. Make sure to order both products.


 

 

 

Accessories

Evidence

Proven durability

In over 30 years of successful implants, the Mitroflow valve has consistently demonstrated excellent hemodynamic performance, ease of implant and proven durability.

Thanks to its unique design, Mitroflow offers surgeons the option, based on anatomy, of supra-annular or intra-annular valve placement even in patients with very small annuli.

The Mitroflow Aortic Pericardial Heart Valve has demonstrated: 

  • Excellent valve hemodynamics1,2,3
  • Proven durability 4,5,6

 

REFERENCES

  1. Asch FM, et al. Mitroflow Aortic Bioprosthesis 5-Year Follow-Up: North American Prospective Multicenter Study. Ann Thorac Surg. 2012;94:1198-1203.

  2. Jamieson WR, Forgie WR, Hayden RI et al. Hemodynamic performance of mitroflow aortic pericardial bioprosthesis – optimizing management for the small aortic annulus. J Thorac Cardiovasc Surg. 2010;58:69–75.

  3. Bleiziffer S, Eichinger WB, Hettich IM et al. Hemodynamic characterization of the Sorin Mitroflow pericardial bioprosthesis at rest and exercise. J Heart Valve Dis. 2009;18:95–100.

  4. The ISTHMUS Investigators. The Italian study on the Mitroflow postoperative results (ISTHMUS): A 20-year, multicentre evaluation of Mitroflow pericardial bioprosthesis. Eur J Cardiothorac Surg. 2011;39:18–26.

  5. Yankah C, Pasic M, Musci M et al. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: durability results up to 21 years. J Thorac Cardiovasc Surg. 2008;136:688–96.

  6. Yankah, C. Mitroflow pericardial aortic bioprosthesis in patients younger than 60 years. J Thorac Cardiovasc Surg. 2010;140:e83–4.

Download Area

  • Sorin Magnetic Resonance Document (M-00000 F) download 694.05 kB application/pdf

This product may not be for sale in your country or your area. For further information on product availability, please contact your local representative

Version unknown | Revision 110937 | Status unstable | SessionId 607E6E33A99852F9375F9AB7516ED962.jvm1